The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity.
Abstract
PURPOSE: To identify the major sites of platinum accumulation within neural tissues after treatment with cisplatin and to determine the relationship between cumulative dosage, time, and the development of histopathological and clinical neurotoxicity. PATIENTS AND METHODS: Twenty-one patients treated antemortem with cisplatin had neural tissue harvested at autopsy. Neural tissues were assayed for platinum and examined for histopathologic evidence of neurotoxicity. The relationship between histopathologic neurotoxicity and various pharmacologic parameters was analyzed. RESULTS: Tissue platinum levels were found to be highest in the dorsal root ganglia and lowest in tissue protected by the blood-brain barrier. For peripheral nerve, dorsal root, and dorsal root ganglia, a linear relationship was observed between platinum levels and cumulative dose. Platinum levels in neural tissue were not observed to decrease with time. Histopathologic toxicity closely matched an index of exposure to platinum (cumulative dose and log of time). Clinical and histopathologic neurotoxicity was found to occur with higher accumulations of platinum, with the highest levels found in patients with clinical evidence of neurotoxicity. CONCLUSIONS: The dorsal root ganglia was the most vulnerable neural structure. This is consistent with the clinical presentation of sensory neuropathy in cisplatin neurotoxicity. Central structures of the spinal cord and brain were protected from platinum accumulation. The increasing histopathologic toxicity, with an index of exposure to platinum, suggests that it is retained indefinitely in an actively neurotoxic form. The pharmacologic parameters examined correlate with the development of and are consistent with the clinical and laboratory features of cisplatin neurotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
EINHORN, L. H., & DONOHUE, J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-293 · Cited by 1,545
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e · Cited by 1,090
Gralla, R. J., Itri, L. M., Pisko, S. E., Squillante, A. E., Kelsen, D. P., Braun, D. W., Bordin, L. A., Braun, T. J., & Young, C. W. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110153051601 · Cited by 705
Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies
Thompson, S. W., Davis, L. E., Kornfeld, M., Hilgers, R. D., & Standefer, J. C. (1984) · Cancer · doi:10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9 · Cited by 394
Peripheral sensory neuropathy and cisplatin chemotherapy
Roelofs, R. I., Hrushesky, W., Rogin, J., & Rosenberg, L. (1984) · Neurology · doi:10.1212/wnl.34.7.934 · Cited by 370
Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy
Sallan, S. E., Zinberg, N. E., & Frei, E. (1975) · New England Journal of Medicine · doi:10.1056/nejm197510162931603 · Cited by 364
High-Dose Cisplatin in Hypertonic Saline
OZOLS, R. F., CORDEN, B. J., JACOB, J., WESLEY, M. N., OSTCHEGA, Y., & YOUNG, R. C. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-1-19 · Cited by 333
VP-16 and cisplatin as first-line therapy for small-cell lung cancer.
Evans, W. K., Shepherd, F. A., Feld, R., Osoba, D., Dang, P., & Deboer, G. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.11.1471 · Cited by 317
Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer
van der Hoop, R. G., Vecht, C. J., van der Burg, M. E. L., Elderson, A., Boogerd, W., Heimans, J. J., Vries, E. P., van Houwelingen, J. C., Jennekens, F. G. I., Gispen, W. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220204 · Cited by 287
Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
Mollman, J. E., Glover, D. J., Hogan, W. M., & FURMAN, R. E. (1988) · Cancer · doi:10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a · Cited by 219
Antiemetic Efficacy of Dexamethasone
Markman, M. M., Sheidler, V. R., Ettinger, D. S., Quaskey, S. A., & Mellits, E. D. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408303110901 · Cited by 175
Kris, M. G., Gralla, R. J., Clark, R. A., & Tyson, L. B. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.4.659 · Cited by 121
Stoter, G., Sleijfer, D. T., Vendrik, C. P. J., et al. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91719-7 · Cited by 97
Stewart, D. J., Mikhael, N. Z., Nanji, A. A., Nair, R. C., Kacew, S., Howard, K., Hirte, W., & Maroun, J. A. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.9.1251 · Cited by 66
Self-citation
Cited by
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Zajączkowska, R., Kocot-Kępska, M., Leppert, W., Wrzosek, A., Mika, J., & Wordliczek, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061451 · Cited by 829
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Starobova, H., & Vetter, I. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00174 · Cited by 648
Chemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Metadata
- Authors
- Gregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1992-05
- Volume
- 10
- Issue
- 5
- Pages
- 795-803
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1832113570
- Cited by
- 358
- References
- 15
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.